A large number of studies have focused on mental health declines associated with glaucoma. For example, about one-third of ...

According to the company, in a confirmatory trial, Epioxa met pre-specified primary efficacy endpoint and exhibited positive ...

The Center, which was launched in 2023, will now be named The Barry Family Center for Ophthalmic Artificial Intelligence and ...

Corneal cross-linking has led to a significant decline in corneal transplant rates for keratoconus globally. Cross-linking ...

Centricity Vision announced new ZEPTOLink enhancements, reducing treatment time by up to 60%. These updates, aimed at ...

David Eichenbaum, MD and Riad Sherif, MD, CEO of Oculis will present the updates with additional info on topline results from ...

The DOG recognised Heidelberg Engineering founder Christoph Schoess, Prof Herbert Kaufmann, and Prof Ioannis G. Pallikaris ...

According to the company, enVista Envy IOLs will be commercially available in the U.S. on a limited basis in the coming weeks ...

The FDA granted approval to the enVista Envy full range of vision IOLs following Canadian approval in May 2024.

AD is a neurodegenerative disease characterized by neuronal loss in the cerebral cortex and the formation of extracellular ...

Artificial intelligence has the potential to improve ophthalmology practices by streamlining documentation, enhancing ...

The phase 3 clinical trial is a randomized, double-blind, three-arm study comparing MELT-300, sublingual midazolam, and ...